The IM83 CAR-T cell therapy, targeting GPC3 antigen, is positioned to address a significant unmet need in advanced hepatocellular carcinoma (HCC), particularly in patients who have failed first-line treatments. The market for liver cancer therapies is growing, driven by increasing incidence rates and a lack of effective second-line options. Given the specificity of the GPC3 target, IM83 may offer a competitive edge over existing therapies, particularly in the CAR-T space. However, the asset's success will depend on the outcomes of the ongoing trial and the competitive landscape, which includes other CAR-T therapies and novel systemic treatments for liver cancer.